Catalyst Pharmaceuticals announces multiple abstracts on FYCOMPA

Catalyst Pharmaceuticals (CPRX) announced that multiple abstracts highlighting FYCOMPA CIII will be presented at the upcoming 35th International Epilepsy Congress, IEC, taking place on September 2 – 6, 2023 in Dublin, Ireland. These are presentations by Eisai (ESAIY), which holds the rights to FYCOMPA in countries and regions outside the U.S. Some abstracts will also be considered for publication in Epilepsia following the IEC. “These findings, which are being presented at IEC, further validate and add to the growing body of evidence supporting the benefits of perampanel in the treatment of seizure disorders,” said Gary Ingenito, MD, PhD, Chief Medical and Regulatory Officer of Catalyst. “We are pleased this investigative work will be presented at such a prestigious forum.”